inSignals Neurotech

InSignals Neurotech is a tech-based company dedicated to developing innovative solutions that enhance therapies and promote improved well-being among patients with neuromuscular disorders. Established in 2019 as a spin-off from INESC TEC/University of Porto, with the licensing rights to the patented wearable motion quantification technology, known as "iHandU," from the esteemed Biomedical Research And INnovation” (a.k.a BRAIN) lab.

InSignals is a prestigious company founded by the internationally renowned R&D center, INESC TEC at the University of Porto, in collaboration with Prof. João Paulo Cunha, the leader of the BRAIN lab at INESC TEC, and Frontier IP Group, a British organization specialized in IP commercialization. Prof. João Cunha is a distinguished researcher in Neuro-Engineering and Advanced Human Sensing technologies, with extensive contributions to the field. INESC TEC is a well-known research institute in Portugal, driving scientific innovation and fostering collaboration between academia, industry, and society. Frontier IP Group works closely with universities and research institutions to promote promising technologies with commercial potential. In 2021, Portugal Ventures, a venture capital firm supporting innovative startups, joined InSignals as a seed investor, further enhancing the company's growth prospects.
 

Our mission is to revolutionize the assessment of motor symptoms in neuromuscular disorders, targeting unmet needs in healthcare treatments. We strive to improve the quality of life for patients by developing innovative solutions that promote personalized care and support long-term disease management. Through our cutting-edge technology and data-driven approaches, we are empowering healthcare providers and patients, enabling more accurate diagnoses, tailored treatments, and better overall outcomes. Our mission is driven by a commitment to advancing the field of neurology and making a meaningful impact on the lives of individuals affected by neuromuscular disorders, starting with Parkinson’s Disease (PD). 

We believe in the power of healthcare systems evolving to gather individualized information from patients, leading to enhanced disease management capabilities and personalized treatment plans. By leveraging innovation, we aim to enable healthcare providers to make informed decisions, deliver targeted therapies, and empower patients to actively participate in their own disease management. Our vision is to create a paradigm shift in how neuromuscular disorders are understood, diagnosed, and treated, ultimately leading to improved patient outcomes and a higher quality of life.